Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

• Status: Completed
• Trial end date: 2020-04-23
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura when administered in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IVERIC bio, Inc.; Ophthotech Corporation

Criteria

Inclusion Criteria:

• Subjects of either gender aged ≥ 50 years

• Diagnosis of Non-foveal GA secondary to dry AMD

Exclusion Criteria:

• Evidence of Choroidal Neovascularization (CNV)

• GA secondary to any condition other than AMD

• Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals

• Any intraocular surgery or thermal laser within three (3) months of trial entry

• Any prior thermal laser in the macular region, regardless of indication

• Any ocular or periocular infection in the twelve (12) weeks

• Previous therapeutic radiation in the region of the study eye

• Any sign of diabetic retinopathy in either eye